Viewing data from:

ELETRIPTAN HYDROBROMIDE

ANDA

ELETRIPTAN HYDROBROMIDE | A205152 | MYLAN PHARMACEUTICALS INC

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: RELPAX(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 3 NDCs

Highest NADAC/Unit

$1.94

per ea

Lowest NADAC/Unit

$1.91

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378428785ELETRIPTAN HBR 20 MG TABLET	$1.94	EA	Generic	—	2026-08-19
00378428808ELETRIPTAN HBR 40 MG TABLET	$1.91	EA	Generic	—	2026-08-19
00378428885ELETRIPTAN HBR 40 MG TABLET	$1.91	EA	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain10 active DMFs2 inactive

8 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVELETRIPTAN HYDROBROMIDE

DMF 229122009

MATRIX PHARMACORP PRIVATE LTDELETRIPTAN HYDROBROMIDE (PROCESS 1)

DMF 245042010

FIS FABBRICA ITALIANA SINTETICI SPAELETRIPTAN HYDROBROMIDE

DMF 245282010

SMS PHARMACEUTICALS LTDELETRIPTAN HYDROBROMIDE MONOHYDRATE

DMF 249052011

MATRIX PHARMACORP PRIVATE LTDELETRIPTAN HYDROBROMIDE (PROCESS 2)

DMF 250762011

HETERO DRUGS LTDELETRIPTAN HYDROBROMIDE

DMF 260992012

YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTDELETRIPTAN HYDROBROMIDE "YUNG SHIN"

DMF 296162015

TIANJIN WEIJIE PHARMACEUTICAL CO LTDELETRIPTAN HYDROBROMIDE

DMF 303382016

APITORIA PHARMA PRIVATE LTDELETRIPTAN HYDROBROMIDE

DMF 313362017

SMS PHARMACEUTICALS LTDELETRIPTAN HYDROBROMIDE

DMF 421282025

APOTEX PHARMACHEM INDIA PVT LTDInactiveELETRIPTAN HYDROBROMIDE

DMF 236512010

VIWIT PHARMACEUTICAL CO LTDInactiveELETRIPTAN HYDROBROMIDE (DRUG SUBSTANCE, NON-STERILE)

DMF 270692013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 20MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Aug 11, 2017

No patent or exclusivity listings for this strength.

#002 — EQ 40MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Aug 11, 2017